Mylan obtains licence in settlement of venlafaxine XR patent dispute
This article was originally published in Scrip
Executive Summary
Mylan says that its subsidiary Mylan Pharmaceuticals has entered into a settlement of US patent infringement litigation with Wyeth (now part of Pfizer) relating to a generic version of Wyeth's extended-release venlafaxine product, Effexor XR. Mylan, along with several other generics firms, now has a definite launch date.